Pure erythroid leukemia following precursor B-cell lymphoblastic leukemia

Area of Science:

• Hematology
• Oncology
• Cancer Research

Background:

• Multimodal intensive chemotherapy is standard for acute lymphoblastic leukemia (ALL).
• Therapy-related acute myeloid leukemia (t-AML) is a known complication of chemotherapy.
• Pure erythroleukemia (AML-M6b) is a rare subtype of AML.

Observation:

• A patient undergoing treatment for precursor B-cell ALL developed a secondary hematologic malignancy.
• The secondary malignancy was diagnosed as pure erythroleukemia (AML-M6b).

Findings:

• This case represents the first reported instance of AML-M6b occurring as a therapy-related malignancy in a patient with precursor B-cell ALL.
• The findings highlight the potential for unusual hematologic sequelae following intensive ALL treatment.

Implications:

• This case underscores the importance of vigilance for secondary malignancies in patients treated for ALL.
• Further research may be needed to understand the specific mechanisms linking ALL therapy to the development of AML-M6b.
• This report contributes to the understanding of rare chemotherapy-induced cancers.